Prevalence and predictors of deterioration of a trustful patient-provider relationship among HIV-infected persons treated with antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 47, Issue 4, 2008, Pages 467-471

  Préau, Marie ^a,b,c   Leport, Catherine ^d   Villes, Virginie ^a,c   Michelet, Christian ^e   Collin, Fidéline ^b   Carrieri, Maria Patrizia ^a,c   Ragnaud, Jean Marie ^f   Taieb, Audrey ^b   Raffi, François ^g,h   Spire, Bruno ^a,b,c   Leport, C ^h   Chene G ^h   Salamon, R ^h   Moatti, J P ^h   Pierret, J ^h   Spire, B ^h   Brun Vezinet F ^h   Fleury, H ^h   Peytavin, G ^h   Garraffo, R ^h   Costagliola, D ^h   Dellamonica, P ^h   Katlama, C ^h   Meyer, L ^h   Morin, M ^h   Sicard, D ^h   Sobel, A ^h   Ballereau, F ^h   Choutet, P ^h   Delfraissy, J F ^h   Dormon, J ^h   Bursachi, P ^h   Garre M ^h   more..

^a UNIVERSITÉ DE NANTES   (France)

^b INSERM   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d Department of Epidemiology   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f HÔPITAL PELLEGRIN   (France)

^g HÔTEL DIEU   (France)

^h Hotel Dieu Hospital ^*

Author keywords

Highly active antiretroviral therapy; Patient provider relationship; Self reported side effects; Trust

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; CONTROLLED STUDY; DISEASE TRANSMISSION; DOCTOR PATIENT RELATION; FEMALE; FOLLOW UP; HEALTH CARE DELIVERY; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; STATISTICAL ANALYSIS; TREATMENT PLANNING; VIRUS LOAD;

EID: 40549097741     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31815f3bdc     Document Type: Article

References (51)

1. CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158-1159.
2. Sabin CA. The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS. 2002;16(Suppl 4):S61-S68.
3. Allardice GM, McMenamin JJ, Parpia T, et al. The recent impact of antiretroviral combination therapy on CD4 counts, AIDS and death in HIV-infected persons: routine HIV surveillance in Scotland. Int J STD AIDS. 1998;9:561-566.
4. Allen LL, Haririfar M, Cohen J, et al. Quality of life and locus of control of migraineurs. Clin Excell Nurse Pract. 2000;4:41-49.
5. Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998;352:1725-1730.
6. Ford S, Fallowfield L, Lewis S. Doctor-patient interactions in oncology. Soc Sci Med. 1996;42:1511-1519.
7. Garcia R, Lima MG, Gorender M, et al. The importance of the doctor-patient relationship in adherence to HIV/AIDS treatment: a case report. Braz J Infect Dis. 2005;9:251-256.
8. Detmar SB, Muller MJ, Schornagel JH, et al. Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002;288:3027-3034.
9. Preau M, Leport C, Salmon-Ceron D, et al. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. AIDS Care. 2004;16:649-661.
10. Levine JS. Trust: can we create the time? Arch Intern Med. 2004;164:930-932.
11. Price J, Leaver L. ABC of psychological medicine: beginning treatment. BMJ. 2002;325:33-35.
12. Tiamson ML. Challenges in the management of the HIV patient in the third decade of AIDS. Psychiatr Q. 2002;73:51-58.
13. Meier RH 3rd, Purtilo RB. Ethical issues and the patient-provider relationship. Am J Phys Med Rehabil. 1994;73:365-366.
14. Hall JA, Roter DL. Do patients talk differently to male and female physicians? A meta-analytic review. Patient Educ Couns. 2002;48:217-224.
15. Hall JA, Roter DL, Katz NR. Meta-analysis of correlates of provider behavior in medical encounters. Med Care. 1988;26:657-675.
16. Roter D, Larson S. The Roter interaction analysis system (RIAS): utility and flexibility for analysis of medical interactions. Patient Educ Couns. 2002;46:243-251.
17. Roter DL, Hall JA, Aoki Y. Physician gender effects in medical communication: a meta-analytic review. JAMA. 2002;288:756-764.
18. Casebeer L, Bennett N, Kristofco R, et al. Physician Internet medical information seeking and on-line continuing education use patterns. J Contin Educ Health Prof. 2002;22:33-42.
19. Craan F, Oleske DM. Medical information and the Internet: do you know what you are getting? J Med Syst. 2002;26:511-518.
20. Mullins CD. The increasing use of the Internet for obtaining medical information. Clin Ther. 2004;26:284.
21. Nabarette H, Lermechin H, Ayme S. [Access to medical information on the Internet: inequality observed in the site audience.] Rev Epidemiol Sante Publique. 2005;53:211-216.
22. Mechanic D. Changing medical organization and the erosion of trust. Milbank Q. 1996;74:171-189.
23. Mechanic D. In my chosen doctor I trust. BMJ. 2004;329:1418-1419.
24. Kao AC, Green DC, Davis NA, et al. Patients' trust in their physicians: effects of choice, continuity, and payment method. J Gen Intern Med. 1998;13:681-686.
25. Kao AC, Green DC, Zaslavsky AM, et al. The relationship between method of physician payment and patient trust. JAMA. 1998;280:1708-1714.
26. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort. J Acquir Immune Defic Syndr. 2001;28:232-239.
27. Carrieri P, Spire B, Duran S, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;32:38-47.
28. Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38-45.
29. Spire B, Duran S, Souville M, et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54:1481-1496.
30. Preau M, Vincent E, Spire B, et al. Health-related quality of life and health locus of control beliefs among HIV-infected treated patients. J Psychosom Res. 2005;59:407-413.
31. Preau M, Bouhnik AD, Spire B, et al. [Health related quality of life and lipodystrophy syndrome among HIV-infected patients.] Encephale. 2006;32:713-719.
32. Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441-2444.
33. Peretti-Watel P, Spire B, Lert F, et al. Drug use patterns and adherence to treatment among HIV-infected patients: evidence from a large sample of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 2006;82(Suppl 1);S71-S79.
34. Fuhrer R, Rouillon F. The French version of the CES-D scale. Description and translation of the autoevaluation scale [in French]. Psychiatrie et Psychobiologie. 1989;4:163-166.
35. Russell J, Krantz S, Neville S. The patient-provider relationship and adherence to highly active antiretroviral therapy. J Assoc Nurses AIDS Care. 2004;15:40-47.
36. Carrieri MP, Raffi F, Lewden C, et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study. Antivir Ther. 2003;8:585-594.
37. Ellerbeck EF, Choi WS, McCarter K, et al. Impact of patient characteristics on physician's smoking cessation strategies. Prev Med. 2003;36:464-470.
38. Michels PJ, Keisler D. Psychological, demographic and situational factors of family physicians which influence cigarette cessation interventions in office-based practice. Patient Educ Couns. 1994;24:63-71.
39. Turner J, Page-Shafer K, Chin DP, et al. Adverse impact of cigarette smoking on dimensions of health-related quality of life in persons with HIV infection. AIDS Patient Care STDS. 2001;15:615-624.
40. Cook JA, Cohen MH, Burke J, et al. Effects of depressive symptoms and mental health quality of life on use of highly active antiretroviral therapy among HIV-seropositive women. J Acquir Immune Defic Syndr. 2002;30:401-409.
41. Wewers MD, Diaz PT, Wewers ME, et al. Cigarette smoking in HIV infection induces a suppressive inflammatory environment in the lung. Am J Respir Crit Care Med. 1998;158:1543-1549.
42. Doescher MP, Saver BG. Physicians' advice to quit smoking. The glass remains half empty. J Fam Pract. 2000;49:543-547.
43. Gulliford M, Naithani S, Morgan M. What is 'continuity of care'? J Health Serv Res Policy. 2006;11:248-250.
44. Deleted in proof.
45. Bouhnik AD, Preau M, Vincent E, et al. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy. Antivir Ther. 2005;10:53-61.
46. Catz SL, Meredith KL, Mundy LM. Women's HIV transmission risk perceptions and behaviors in the era of potent antiretroviral therapies. AIDS Educ Prev. 2001;13:239-251.
47. Levy-Dweck S. HIV/AIDS fifty and older: a hidden and growing population. J Gerontol Soc Work. 2005;46:37-50.
48. Eldred S, West L. HIV prevalence in older adults. Can Nurse. 2005;101:20-23.
49. Shippy RA, Karpiak SE. The aging HIV/AIDS population: fragile social networks. Aging Ment Health. 2005;9:246-254.
50. Bulik RJ. Perspectives on the patient-provider relationship in primary-care telemedicine. Telemed J E Health. 2004;10:466-468.
51. Roeloffs C, Sherbourne C, Unutzer J, et al. Stigma and depression among primary care patients. Gen Hosp Psychiatry. 2003;25:311-315.